Bacil Pharma (524516) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended 31 December 2024; meeting held on 21 January 2025.

• Statutory auditor issued an unmodified review report, with an emphasis of matter on outstanding loans and advances lacking confirmation.

Financial highlights

• Revenue from operations was nil; other income for Q3 FY25 was ₹0.25 lakh, down from ₹3.29 lakh in Q2 FY25 and ₹10.93 lakh in Q3 FY24.

• Net loss for Q3 FY25 was ₹4.80 lakh, compared to net profit of ₹26.37 lakh in Q2 FY25 and net profit of ₹0.05 lakh in Q3 FY24.

• For the nine months ended 31 December 2024, net profit was ₹42.82 lakh, up from ₹14.44 lakh for the same period last year.

• Basic and diluted EPS for Q3 FY25 was (₹0.10), compared to ₹0.82 in Q2 FY25 and (₹0.04) in Q3 FY24.

Outlook and guidance

• No explicit forward-looking guidance provided; financials reflect continued reliance on other income and absence of core operating revenue.